Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe, North America, Latin America and Asia-Pacific: 1,845 cases from 38 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by regionAll jurisdictions
What for?
by area of lawAll areas of law
Who?
by company- Purdue Pharma L.P. €4.75bn 78 % · 1 case
- Teva Pharmaceutical Industries (Teva-Gruppe) €462.6m 8 % · 1 case
- Teva Pharmaceuticals USA, Inc. und Teva Neuroscience, Inc. €411.6m 7 % · 1 case
- Gilead Sciences, Inc. €177.8m 3 % · 1 case
- Pfizer Inc. (für die Tochter Biohaven Pharmaceutical Holding Company Ltd.) €57.1m 1 % · 1 case
- Anonymised companies €49.1m 1 % · 4 cases
- Novamont S.p.A., Eni S.p.A. €32.1m 1 % · 1 case
- Dompé U.S. Inc. €27.5m 0 % · 1 case
- Vifor Pharma UK Limited u. a. (CSL-Konzern) €27.4m 0 % · 1 case
- The Chemours Company; The Chemours Company FC, LLC €19.8m 0 % · 1 case
- 24 more€44.3m
When?
per quarter, by date of decision| Period | Cases | Total |
|---|---|---|
| Q4 2023 | 0 | – |
| Q1 2024 | 0 | – |
| Q2 2024 | 0 | – |
| Q3 2024 | 0 | – |
| Q4 2024 | 0 | – |
| Q1 2025 | 0 | – |
| Q2 2025 | 1 | €32.1m |
| Q3 2025 | 0 | – |
| Q4 2025 | 0 | – |
| Q1 2026 | 0 | – |
| Q2 2026 | 0 | – |
| Q3 2026 | 0 | – |
| Q4 2026 | 0 | – |
1 case
10 Jun 2025 Novamont S.p.A., Eni S.p.A.AGCM fines Novamont and Eni €32.1m over exclusivity ties in bioplastics €32.1m
According to the AGCM, from at least January 2018 to December 2023 Novamont tied film producers to its bioplastic Mater-Bi through exclusive or semi-exclusive purchasing obligations and tied retail chains to carrier bags made by its licensees, thereby excluding competitors in bio-compounds for lightweight and very lightweight plastic carrier bags (Art. 102 TFEU). Novamont must pay 30,359,000 EUR (capped at the 10% turnover limit); for the period after its acquisition by the Eni group on 18 October 2023, Novamont and Eni are jointly and severally liable for a further 1,701,052.08 EUR, a total of 32,060,052.08 EUR.
A compliance programme must address the specific competition risks of the business, such as exclusivity clauses used by a strong supplier, or it will not reduce the fine.
Exclusivity clauses of dominant suppliers and effective compliance programmes
Missing or inadequate training played a role in the decision.
- Authority / court
- Autorità Garante della Concorrenza e del Mercato (AGCM)
- Area of law
- Competition law · Abuse of market power
- Legal basis
- Art. 102 AEUV; Art. 15 Legge n. 287/1990
- Action
- Fine
- Status of proceedings
- unknown
- Sector
- Chemicals and pharmaceuticals
- Mitigating circumstances
- None recognised: the compliance programme of the Eni group, which Novamont joined in October 2023, had not worked effectively because training and controls covered other topics and exclusive contracts continued to be concluded; the AGCM considered Novamont's earlier programme manifestly inadequate, partly because its competition law manual did not specifically address exclusive purchasing obligations among the forms of abuse.
- Published
- 24 Jun 2025
- AGCM, Provvedimento A573 (Adunanza 10.06.2025), Chiusura istruttoria e sanzioni Decision of an authority
- AGCM, Comunicato stampa 24.06.2025: A573 – sanzioni complessivamente pari a oltre 32 milioni di euro a Novamont e alla controllante Eni Press release of an authority
Checked against the official source on 28 Sep 2026 · Direct link